Guardant Health appeals Delaware court judgment in TwinStrand patent dispute

• Guardant Health will appeal a final judgment from the U.S. District Court in Delaware in an IP case brought by TwinStrand Biosciences, University of Washington.
• Execution of the judgment, collection of potential royalties stayed pending the appeal.
• Royalty order covers products that existed at the 2023 trial; current Guardant Reveal, Shield excluded from potential royalties.
• Design changes to Guardant360 validated to avoid impact of potential ongoing royalties.
• TwinStrand patents preliminarily invalidated in related U.S. Patent and Trademark Office challenges; separate Federal Circuit appeals ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608241444BIZWIRE_USPR_____20260824_BW854156) on August 24, 2026, and is solely responsible for the information contained therein.